Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.71 EUR
Change Today -0.018 / -0.66%
Volume 0.0
LT3 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 1:36 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

axogen inc (LT3) Snapshot

Open
€2.74
Previous Close
€2.73
Day High
€2.77
Day Low
€2.68
52 Week High
01/8/15 - €3.53
52 Week Low
08/15/14 - €1.61
Market Cap
67.6M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
24.9M
EX-Date
01/27/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AXOGEN INC (LT3)

Related News

No related news articles were found.

axogen inc (LT3) Related Businessweek News

No Related Businessweek News Found

axogen inc (LT3) Details

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offers AxoTouch Two Point Discriminator, a measurement tool for determining innervation density and sensory function. The company’s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It markets its products in the United States, the United Kingdom, Singapore, Israel, Canada, Switzerland, Austria, and Spain. AxoGen, Inc. is headquartered in Alachua, Florida.

84 Employees
Last Reported Date: 03/5/15

axogen inc (LT3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $473.3K
Chief Financial Officer
Total Annual Compensation: $220.9K
Senior Vice President of Business Development...
Total Annual Compensation: $326.8K
Senior Vice President of Sales
Total Annual Compensation: $384.3K
Chief Marketing Officer
Total Annual Compensation: $311.7K
Compensation as of Fiscal Year 2014.

axogen inc (LT3) Key Developments

AxoGen, Inc. to Report Q1, 2015 Results on May 05, 2015

AxoGen, Inc. announced that they will report Q1, 2015 results After-Market on May 05, 2015

AxoGen, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

AxoGen, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $4.951 million for the first quarter ended March 31, 2015, a 58% increase compared to $3.138 million in the year-ago first quarter. Loss from operations was $2.543 million against $2.991 million a year ago. Net loss was $3.575 million or $0.16 per basic and diluted share against $4.239 million or $0.24 per basic and diluted share a year ago. Net cash used for operating activities was $2.513 million against $3.150 million a year ago. Purchase of property and equipment was $0.006 million against $0.195 million a year ago. Acquisition of intangible assets was $0.032 million against $0.008 million a year ago. For the year 2015, the company announced that given the market's increasing awareness of the company’s product portfolio and the company's plans to expand its sales footprint and sales pipeline, the company is reaffirming its 2015 full year revenue guidance of at least $24 million with annual gross margin in the mid to high 70% range.

AxoGen, Inc., Q1 2015 Earnings Call, May 05, 2015

AxoGen, Inc., Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LT3:GR €2.71 EUR -0.018

LT3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $67.37 USD -0.17
Integra LifeSciences Holdings Corp $67.52 USD -0.57
Stryker Corp $96.44 USD +0.04
View Industry Companies
 

Industry Analysis

LT3

Industry Average

Valuation LT3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AXOGEN INC, please visit www.axogeninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.